董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul B. Bolno | 男 | Director | 52 | 13.44万美元 | 未持股 | 2025-09-22 |
| Terrance McGuire | 男 | Director | 68 | 8.45万美元 | 700.86 | 2025-09-22 |
| Marc Elia | 男 | Director, Chairperson of Board | 49 | 12.60万美元 | 948.99 | 2025-09-22 |
| Ajay Royan | 男 | Director | 45 | 11.02万美元 | 1124.16 | 2025-09-22 |
| Tamsin Berry | 女 | Director | 44 | 8.80万美元 | 24.17 | 2025-09-22 |
| Christine Lindenboom | 女 | Director | 44 | 15.76万美元 | 20.88 | 2025-09-22 |
| Kevin F. McLaughlin | 男 | Director | 68 | 未披露 | 未持股 | 2025-09-22 |
| Paul B. Bolno | 男 | Director | -- | 未披露 | 未持股 | 2025-09-22 |
| Kevin F. McLaughlin | 男 | Director | 69 | 10.16万美元 | 3.33 | 2025-09-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Duke | 男 | Chief Financial Officer | 53 | 214.12万美元 | 48.61 | 2025-09-22 |
| Robert Allen | 男 | Chief Scientific Officer | 56 | 未披露 | 未持股 | 2025-09-22 |
| Jill Andersen | 女 | Chief Legal Officer and Corporate Secretary | 52 | 248.62万美元 | 未持股 | 2025-09-22 |
| Julie Green | 女 | Chief Human Resources Officer | 50 | 158.62万美元 | 40.87 | 2025-09-22 |
| Timothy Lee | 男 | Chief Commercial Officer | 51 | 209.53万美元 | 7.92 | 2025-09-22 |
董事简历
中英对照 | 中文 | 英文- Paul B. Bolno
-
Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine. - Paul B. Bolno，自2013年12月起担任公司的总裁和首席执行官，也是董事。在加入公司之前，他在GlaxoSmithKline担任不同的职位（2009-2013年），包括全球业务拓展副总裁，亚洲（Asia）业务拓展和投资负责人；全球神经科学业务拓展负责人；新加坡（Singapore）Glaxo Welcome Manufacturing, Pte. Ltd.的董事；肿瘤科业务拓展副总裁，他建立了GlaxoSmithKline的全球肿瘤业务并担任肿瘤执行团队、肿瘤商业董事会和癌症研究执行团队的成员。在GlaxoSmithKline之前，他担任Two River 有限责任公司（Two River LLC，一家健康保健私人股权公司）的研究董事（2004-2009年）。他拥有MCP哈内曼医学院（MCP-Hahnemann School of Medicine）医学学位和德雷克塞尔大学（Drexel University）工商管理硕士学位。他是德雷克塞尔大学医学院（Drexel University College of Medicine）的普通外科住院医师和心胸外科博士后研究师。
- Paul B. Bolno has served as President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining Wave Life Sciences, Inc., he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
- Terrance McGuire
-
Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Terrance McGuire,has served as a member of Board since October 2020. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. He currently serves on the boards of directors of Seer, Inc. and Tectonic Therapeutic, Inc., as well as several private companies, including Adimab, LLC. Mr. McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire is also on the Scientific Advisory Board of the Brigham and Women's Hospital. Mr. McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School. - Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Terrance McGuire,has served as a member of Board since October 2020. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. He currently serves on the boards of directors of Seer, Inc. and Tectonic Therapeutic, Inc., as well as several private companies, including Adimab, LLC. Mr. McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire is also on the Scientific Advisory Board of the Brigham and Women's Hospital. Mr. McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.
- Marc Elia
-
Marc Elia自2022年6月起担任董事会成员，自2022年7月起担任董事会主席。他此前曾于2020年7月至2021年4月担任董事会成员。Elia先生是医疗保健行业投资基金M28 Capital Management L.P.的创始人兼首席投资官，自2019年9月以来一直担任该职位。在此之前，从2012年1月到2019年9月，埃利亚先生在投资基金Bridger Capital担任合伙人。埃利亚先生目前担任Fractyl Health，Inc.的董事会成员，该公司是一家公开上市的代谢疗法公司。他此前曾在SQZ生物技术公司和Adimab，LLC的董事会任职。在从事投资职业之前，Elia先生曾在N30 Pharmaceuticals、Chiron Corporation和L.E.K. Consulting的生物技术行业担任过各种职务。
Marc Elia has served as a member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors of Fractyl Health, Inc., a publicly traded metabolic therapeutics company. He previously served on the boards of directors of SQZ Biotechnologies Company and Adimab, LLC. Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting. - Marc Elia自2022年6月起担任董事会成员，自2022年7月起担任董事会主席。他此前曾于2020年7月至2021年4月担任董事会成员。Elia先生是医疗保健行业投资基金M28 Capital Management L.P.的创始人兼首席投资官，自2019年9月以来一直担任该职位。在此之前，从2012年1月到2019年9月，埃利亚先生在投资基金Bridger Capital担任合伙人。埃利亚先生目前担任Fractyl Health，Inc.的董事会成员，该公司是一家公开上市的代谢疗法公司。他此前曾在SQZ生物技术公司和Adimab，LLC的董事会任职。在从事投资职业之前，Elia先生曾在N30 Pharmaceuticals、Chiron Corporation和L.E.K. Consulting的生物技术行业担任过各种职务。
- Marc Elia has served as a member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors of Fractyl Health, Inc., a publicly traded metabolic therapeutics company. He previously served on the boards of directors of SQZ Biotechnologies Company and Adimab, LLC. Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting.
- Ajay Royan
-
Ajay Royan，自2025年3月起担任董事会成员，此前担任董事会成员的时间为2020年10月至2022年6月。Royan先生是创始人，自2012年6月起担任投资于科技公司的风险投资公司Mithril Capital Management LLC的管理普通合伙人。Royan先生目前担任代谢疗法公司Fractyl Health，Inc.的董事会成员，以及Mithril Capital Management LLC或其附属公司投资的几家私营公司的董事会成员，其中包括Adimab，LLC。Royan先生在Fulbright Canada的董事会任职。Royan先生获得了耶鲁大学的学士学位。
Ajay Royan,has served as a member of Board since March 2025, and he previously served as a member of Board from October 2020 until June 2022. Mr. Royan is the founder and has served as Managing General Partner of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012. Mr. Royan currently serves on the board of directors of Fractyl Health, Inc., a metabolic therapeutics company, as well as on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested, including Adimab, LLC. Mr. Royan serves on the board of directors of Fulbright Canada. Mr. Royan received a B.A. from Yale University. - Ajay Royan，自2025年3月起担任董事会成员，此前担任董事会成员的时间为2020年10月至2022年6月。Royan先生是创始人，自2012年6月起担任投资于科技公司的风险投资公司Mithril Capital Management LLC的管理普通合伙人。Royan先生目前担任代谢疗法公司Fractyl Health，Inc.的董事会成员，以及Mithril Capital Management LLC或其附属公司投资的几家私营公司的董事会成员，其中包括Adimab，LLC。Royan先生在Fulbright Canada的董事会任职。Royan先生获得了耶鲁大学的学士学位。
- Ajay Royan,has served as a member of Board since March 2025, and he previously served as a member of Board from October 2020 until June 2022. Mr. Royan is the founder and has served as Managing General Partner of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012. Mr. Royan currently serves on the board of directors of Fractyl Health, Inc., a metabolic therapeutics company, as well as on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested, including Adimab, LLC. Mr. Royan serves on the board of directors of Fulbright Canada. Mr. Royan received a B.A. from Yale University.
- Tamsin Berry
-
Tamsin Berry，自2022年6月起担任董事会成员。Berry女士自2020年6月起担任全球投资公司Population Health Partners的合伙人。自2024年3月起，她受聘于牛津大学埃里森理工学院，担任参谋长（兼职）。从2021年11月到2024年2月，她担任非盈利病原体监测生物信息学公司Global Pathogen Analysis Service的非执行董事，同时也是董事会成员。2021年3月至2023年3月，她担任生物技术公司EQRx，Inc.的顾问。2020年12月至2024年2月，她担任牛津大学全球健康安全联盟顾问，该联盟包括托尼布莱尔研究所。2019年2月至2020年3月，她担任英国生命科学办公室主任，与John Bell爵士合作撰写英国生命科学产业战略。她此前曾担任英国生命科学办公室副主任，2015年11月至2019年2月。贝瑞在政府担任过多个领导职务，在内阁办公室、卫生部和英国公共卫生部担任过政策、企业和沟通方面的职务。从2020年3月到2020年6月，她的最后一份工作是在COVID工作组中，Berry女士在大流行开始时担任血清学和血清阳性率高级责任官，并因其工作获得了OBE。Berry女士获得诺丁汉大学法学学士学位和利兹大学哲学硕士学位。
Tamsin Berry,has served as a member of Board since June 2022. Ms. Berry has served as a partner at Population Health Partners, a global investment firm, since June 2020. Since March 2024, she has been employed by The Ellison Institute of Technology Oxford as the Chief of Staff (part-time). From November 2021 through February 2024, she served as non-executive director, and also as a board member, of the Global Pathogen Analysis Service, a not-for-profit pathogen surveillance bioinformatics company. From March 2021 to March 2023, she served as an advisor to EQRx, Inc., a biotechnology firm. From December 2020 to February 2024, she served as advisor to University of Oxford for the Global Health Security Consortium, which includes the Tony Blair Institute. From February 2019 to March 2020, she served as the director of the U.K. Office for Life Sciences, where she worked with Sir John Bell to write the U.K.'s Life Sciences Industrial Strategy. She previously served as Deputy Director of the U.K. Office for Life Sciences, from November 2015 to February 2019. Ms. Berry has held a number of leadership positions in government, spanning policy, corporate, and communications roles at the Cabinet Office, Department of Health, and Public Health England. From March 2020 to June 2020, her final role was in the COVID Taskforce, where Ms. Berry was the senior responsible officer for serology and seroprevalence at the start of the pandemic and was awarded an OBE for her work. Ms. Berry received a bachelor of laws degree from the University of Nottingham and a master's degree from the University of Leeds in Philosophy. - Tamsin Berry，自2022年6月起担任董事会成员。Berry女士自2020年6月起担任全球投资公司Population Health Partners的合伙人。自2024年3月起，她受聘于牛津大学埃里森理工学院，担任参谋长（兼职）。从2021年11月到2024年2月，她担任非盈利病原体监测生物信息学公司Global Pathogen Analysis Service的非执行董事，同时也是董事会成员。2021年3月至2023年3月，她担任生物技术公司EQRx，Inc.的顾问。2020年12月至2024年2月，她担任牛津大学全球健康安全联盟顾问，该联盟包括托尼布莱尔研究所。2019年2月至2020年3月，她担任英国生命科学办公室主任，与John Bell爵士合作撰写英国生命科学产业战略。她此前曾担任英国生命科学办公室副主任，2015年11月至2019年2月。贝瑞在政府担任过多个领导职务，在内阁办公室、卫生部和英国公共卫生部担任过政策、企业和沟通方面的职务。从2020年3月到2020年6月，她的最后一份工作是在COVID工作组中，Berry女士在大流行开始时担任血清学和血清阳性率高级责任官，并因其工作获得了OBE。Berry女士获得诺丁汉大学法学学士学位和利兹大学哲学硕士学位。
- Tamsin Berry,has served as a member of Board since June 2022. Ms. Berry has served as a partner at Population Health Partners, a global investment firm, since June 2020. Since March 2024, she has been employed by The Ellison Institute of Technology Oxford as the Chief of Staff (part-time). From November 2021 through February 2024, she served as non-executive director, and also as a board member, of the Global Pathogen Analysis Service, a not-for-profit pathogen surveillance bioinformatics company. From March 2021 to March 2023, she served as an advisor to EQRx, Inc., a biotechnology firm. From December 2020 to February 2024, she served as advisor to University of Oxford for the Global Health Security Consortium, which includes the Tony Blair Institute. From February 2019 to March 2020, she served as the director of the U.K. Office for Life Sciences, where she worked with Sir John Bell to write the U.K.'s Life Sciences Industrial Strategy. She previously served as Deputy Director of the U.K. Office for Life Sciences, from November 2015 to February 2019. Ms. Berry has held a number of leadership positions in government, spanning policy, corporate, and communications roles at the Cabinet Office, Department of Health, and Public Health England. From March 2020 to June 2020, her final role was in the COVID Taskforce, where Ms. Berry was the senior responsible officer for serology and seroprevalence at the start of the pandemic and was awarded an OBE for her work. Ms. Berry received a bachelor of laws degree from the University of Nottingham and a master's degree from the University of Leeds in Philosophy.
- Christine Lindenboom
-
Christine Lindenboom，自2022年10月起担任董事会成员。Lindenboom女士目前担任生物制药公司Alnylam Pharmaceuticals, Inc.的首席企业传播官，自2015年9月起任职。在加入Alnylam之前，Lindenboom女士于2013年12月至2015年9月期间担任辉瑞公司事务高级董事。在其职业生涯的早期，Lindenboom女士曾于2006年4月至2013年11月在跨国生物制药公司安进公司担任多个职位，最近一次在她离职时担任媒体关系、全球传播和慈善事业总监。Lindenboom女士目前担任肯德尔广场协会的董事会成员，该协会是位于马萨诸塞州剑桥市的国际公认的创新区。Lindenboom女士获得了东北大学的学士学位。
Christine Lindenboom,has served as a member of Board since October 2022. Ms. Lindenboom currently serves as the Chief Corporate Communications Officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, where she has been employed since September 2015. Prior to Alnylam, Ms. Lindenboom served as Senior Director, Corporate Affairs for Pfizer, Inc. from December 2013 to September 2015. Earlier in her career, Ms. Lindenboom served in various positions at Amgen, Inc., a multinational biopharmaceutical company, from April 2006 to November 2013, most recently serving as Director, Media Relations, Global Communications and Philanthropy at the time of her departure. Ms. Lindenboom currently serves on the board of directors of Kendall Square Association, an internationally recognized innovation district located in Cambridge, MA. Ms. Lindenboom received a B.A. from Northeastern University. - Christine Lindenboom，自2022年10月起担任董事会成员。Lindenboom女士目前担任生物制药公司Alnylam Pharmaceuticals, Inc.的首席企业传播官，自2015年9月起任职。在加入Alnylam之前，Lindenboom女士于2013年12月至2015年9月期间担任辉瑞公司事务高级董事。在其职业生涯的早期，Lindenboom女士曾于2006年4月至2013年11月在跨国生物制药公司安进公司担任多个职位，最近一次在她离职时担任媒体关系、全球传播和慈善事业总监。Lindenboom女士目前担任肯德尔广场协会的董事会成员，该协会是位于马萨诸塞州剑桥市的国际公认的创新区。Lindenboom女士获得了东北大学的学士学位。
- Christine Lindenboom,has served as a member of Board since October 2022. Ms. Lindenboom currently serves as the Chief Corporate Communications Officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, where she has been employed since September 2015. Prior to Alnylam, Ms. Lindenboom served as Senior Director, Corporate Affairs for Pfizer, Inc. from December 2013 to September 2015. Earlier in her career, Ms. Lindenboom served in various positions at Amgen, Inc., a multinational biopharmaceutical company, from April 2006 to November 2013, most recently serving as Director, Media Relations, Global Communications and Philanthropy at the time of her departure. Ms. Lindenboom currently serves on the board of directors of Kendall Square Association, an internationally recognized innovation district located in Cambridge, MA. Ms. Lindenboom received a B.A. from Northeastern University.
- Kevin F. McLaughlin
-
Kevin F. McLaughlin，自2024年5月起担任董事会成员。McLaughlin先生在生物技术、高科技和教育行业拥有超过40年的财务和运营管理经验。2010年至2021年，担任Acceleron Pharma Inc.（“Acceleron”）高级副总裁、首席财务官兼财务主管，直至2021年11月被默沙东 & Co.，Inc.收购。在加入Acceleron之前，他于2009年至2010年担任纤维素生物燃料公司Qteros，Inc.的高级副总裁兼首席财务官，并于2007年至2009年担任出版公司Aptius Education，Inc.的联合创始人、首席运营官和董事。从1996年到2007年，麦克劳克林先生在PRAECIS Pharmaceuticals Incorporated担任过多个行政职务。他加入PRAECIS担任首任首席财务官，后来成为首席运营官，然后是总裁兼首席执行官和董事会成员。他一直担任这一职务，直到将公司出售给GSK plc（前身为葛兰素史克）。McLaughlin先生目前在Vericel Corporation的董事会任职，该公司是一家最近成立的私营生物技术公司。他此前曾在Decibel Therapeutics的董事会任职，直到将其出售给再生元制药，以及Stealth Biotherapeutics的董事会任职，直到该公司被一家风险投资公司私有化。麦克劳克林先生的职业生涯始于Prime Computer，Inc.和ComputerVision Corporation的高级财务职位。McLaughlin先生获得了东北大学的学士学位和巴布森学院F.W. 欧林商学院的工商管理硕士学位。
Kevin F. McLaughlin,has served as a member of Board since May 2024. Mr. McLaughlin has more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries. From 2010 to 2021, he served as Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma Inc. ("Acceleron") until its acquisition by Merck & Co., Inc. in November 2021. Prior to Acceleron, he was Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010, and from 2007 through 2009 was Co-Founder, Chief Operating Officer and a Director of Aptius Education, Inc. a publishing company. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals Incorporated. He joined PRAECIS as its first Chief Financial Officer, later becoming Chief Operating Officer, and then President and Chief Executive Officer and a member of the Board of Directors. He remained in this role until the sale of the company to GSK plc (formerly GlaxoSmithKline). Mr. McLaughlin currently serves on the board of directors of Vericel Corporation and a recently formed private biotech company. He previously served on the board of directors of Decibel Therapeutics, until its sale to Regeneron Pharmaceuticals, and the Board of Directors of Stealth Biotherapeutics, until it was brought private by a venture firm. Mr. McLaughlin began his career in senior financial roles at Prime Computer, Inc. and Computervision Corporation. Mr. McLaughlin received a B.S. from Northeastern University and an M.B.A. from the F.W. Olin Graduate School of Business at Babson College. - Kevin F. McLaughlin，自2024年5月起担任董事会成员。McLaughlin先生在生物技术、高科技和教育行业拥有超过40年的财务和运营管理经验。2010年至2021年，担任Acceleron Pharma Inc.（“Acceleron”）高级副总裁、首席财务官兼财务主管，直至2021年11月被默沙东 & Co.，Inc.收购。在加入Acceleron之前，他于2009年至2010年担任纤维素生物燃料公司Qteros，Inc.的高级副总裁兼首席财务官，并于2007年至2009年担任出版公司Aptius Education，Inc.的联合创始人、首席运营官和董事。从1996年到2007年，麦克劳克林先生在PRAECIS Pharmaceuticals Incorporated担任过多个行政职务。他加入PRAECIS担任首任首席财务官，后来成为首席运营官，然后是总裁兼首席执行官和董事会成员。他一直担任这一职务，直到将公司出售给GSK plc（前身为葛兰素史克）。McLaughlin先生目前在Vericel Corporation的董事会任职，该公司是一家最近成立的私营生物技术公司。他此前曾在Decibel Therapeutics的董事会任职，直到将其出售给再生元制药，以及Stealth Biotherapeutics的董事会任职，直到该公司被一家风险投资公司私有化。麦克劳克林先生的职业生涯始于Prime Computer，Inc.和ComputerVision Corporation的高级财务职位。McLaughlin先生获得了东北大学的学士学位和巴布森学院F.W. 欧林商学院的工商管理硕士学位。
- Kevin F. McLaughlin,has served as a member of Board since May 2024. Mr. McLaughlin has more than 40 years of financial and operating management experience spanning the biotech, high-tech and education industries. From 2010 to 2021, he served as Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma Inc. ("Acceleron") until its acquisition by Merck & Co., Inc. in November 2021. Prior to Acceleron, he was Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010, and from 2007 through 2009 was Co-Founder, Chief Operating Officer and a Director of Aptius Education, Inc. a publishing company. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals Incorporated. He joined PRAECIS as its first Chief Financial Officer, later becoming Chief Operating Officer, and then President and Chief Executive Officer and a member of the Board of Directors. He remained in this role until the sale of the company to GSK plc (formerly GlaxoSmithKline). Mr. McLaughlin currently serves on the board of directors of Vericel Corporation and a recently formed private biotech company. He previously served on the board of directors of Decibel Therapeutics, until its sale to Regeneron Pharmaceuticals, and the Board of Directors of Stealth Biotherapeutics, until it was brought private by a venture firm. Mr. McLaughlin began his career in senior financial roles at Prime Computer, Inc. and Computervision Corporation. Mr. McLaughlin received a B.S. from Northeastern University and an M.B.A. from the F.W. Olin Graduate School of Business at Babson College.
- Paul B. Bolno
-
Paul B. Bolno是临床阶段生物技术公司Wave Life Sciences的总裁兼首席执行官，自2013年以来一直担任这些职务。除了在Wave Life Sciences任职外，他还担任ExpressionEdits的董事会成员，并且是核酸治疗加速器科学咨询小组的主席。
Paul B. Bolno,is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013.In addition to his role at Wave Life Sciences, he serves on the Board of Directors of ExpressionEdits and is the Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator. - Paul B. Bolno是临床阶段生物技术公司Wave Life Sciences的总裁兼首席执行官，自2013年以来一直担任这些职务。除了在Wave Life Sciences任职外，他还担任ExpressionEdits的董事会成员，并且是核酸治疗加速器科学咨询小组的主席。
- Paul B. Bolno,is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013.In addition to his role at Wave Life Sciences, he serves on the Board of Directors of ExpressionEdits and is the Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
- Kevin F. McLaughlin
-
Kevin F. McLaughlin于2018年6月被任命为Stealth BioTherapeutics公司的董事。他曾担任Stealth Delaware的董事（2017年3月以来）。McLaughlin先生目前是Acceleron Pharma， Inc.（生物技术公司）的高级副总裁、首席财务官和财务主管，自2010年11月以来。McLaughlin先生还担任Vericel Corporation（生物制药公司）的董事会成员（2015年1月以来）。他曾担任Qteros， Inc.（纤维素生物燃料公司）的高级副总裁兼首席财务官（2009年至2010年），以及Aptius Education， Inc.（出版公司）的联合创始人、首席运营官和董事（2007年至2009年）。从1996年到2007年，McLaughlin先生担任PRAECIS Pharmaceuticals， Inc.（一家生物制药公司）的多个行政职务，最初担任首席财务官，之后担任首席运营官，最终担任总裁兼首席执行官，他还担任董事会成员。McLaughlin先生的职业生涯始于他在Prime Computer和Computervision Corporation担任高级财务职务。McLaughlin先生获得Northeastern大学的商业学士学位和Babson College的工商管理硕士学位。
Kevin F. McLaughlin was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since March 2017. Mr. McLaughlin is currently Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma, Inc., a biotechnology company, and has been since November 2010. Mr. McLaughlin has also served on the board of directors of Vericel Corporation, a biopharmaceutical company, since January 2015. He previously served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010 and as co-founder, Chief Operating Officer and director of Aptius Education, Inc., a publishing company, from 2007 through 2009. Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc., a biopharmaceutical company, from 1996 through 2007 initially as Chief Financial Officer, before becoming Chief Operating Officer and eventually President and Chief Executive Officer, and he served as a member of the board of directors. Mr. McLaughlin began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A. from Babson College. - Kevin F. McLaughlin于2018年6月被任命为Stealth BioTherapeutics公司的董事。他曾担任Stealth Delaware的董事（2017年3月以来）。McLaughlin先生目前是Acceleron Pharma， Inc.（生物技术公司）的高级副总裁、首席财务官和财务主管，自2010年11月以来。McLaughlin先生还担任Vericel Corporation（生物制药公司）的董事会成员（2015年1月以来）。他曾担任Qteros， Inc.（纤维素生物燃料公司）的高级副总裁兼首席财务官（2009年至2010年），以及Aptius Education， Inc.（出版公司）的联合创始人、首席运营官和董事（2007年至2009年）。从1996年到2007年，McLaughlin先生担任PRAECIS Pharmaceuticals， Inc.（一家生物制药公司）的多个行政职务，最初担任首席财务官，之后担任首席运营官，最终担任总裁兼首席执行官，他还担任董事会成员。McLaughlin先生的职业生涯始于他在Prime Computer和Computervision Corporation担任高级财务职务。McLaughlin先生获得Northeastern大学的商业学士学位和Babson College的工商管理硕士学位。
- Kevin F. McLaughlin was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since March 2017. Mr. McLaughlin is currently Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma, Inc., a biotechnology company, and has been since November 2010. Mr. McLaughlin has also served on the board of directors of Vericel Corporation, a biopharmaceutical company, since January 2015. He previously served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010 and as co-founder, Chief Operating Officer and director of Aptius Education, Inc., a publishing company, from 2007 through 2009. Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc., a biopharmaceutical company, from 1996 through 2007 initially as Chief Financial Officer, before becoming Chief Operating Officer and eventually President and Chief Executive Officer, and he served as a member of the board of directors. Mr. McLaughlin began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A. from Babson College.
高管简历
中英对照 | 中文 | 英文- William Duke
William Duke自2014年1月以来担任我们的首席财务总监。2011年7月他加入Valeritas，担任公司主管。加入Valeritas之前，2010年1至7月2011年1月Duke先生是Genzyme Corporation（一家生物制药公司）的财务高级总监，在那里他负责美国证券交易委员会的外部报告、内部管理报告和全球财务整合。在Genzyme Corporation之前，2008年5月至2010年1月他是Haemonetics Corporation（一家医疗器械公司）的财务董事，并在咨询服务和新兴成长型企业担任各种高级财务职务。Duke先生拥有 Stonehill College的会计学士学位和 Bentley University的金融工商管理硕士学位，是一名注册会计师。
William Duke joined Valeritas as Corporate Controller in July 2011. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporation, a biopharmaceutical company, from January 2010 to July 2011 where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporation, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations. Mr. Duke holds a B.S. in Accounting from Stonehill College and an M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.- William Duke自2014年1月以来担任我们的首席财务总监。2011年7月他加入Valeritas，担任公司主管。加入Valeritas之前，2010年1至7月2011年1月Duke先生是Genzyme Corporation（一家生物制药公司）的财务高级总监，在那里他负责美国证券交易委员会的外部报告、内部管理报告和全球财务整合。在Genzyme Corporation之前，2008年5月至2010年1月他是Haemonetics Corporation（一家医疗器械公司）的财务董事，并在咨询服务和新兴成长型企业担任各种高级财务职务。Duke先生拥有 Stonehill College的会计学士学位和 Bentley University的金融工商管理硕士学位，是一名注册会计师。
- William Duke joined Valeritas as Corporate Controller in July 2011. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporation, a biopharmaceutical company, from January 2010 to July 2011 where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporation, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations. Mr. Duke holds a B.S. in Accounting from Stonehill College and an M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.
- Robert Allen
罗伯特·艾伦，自2023年4月起担任首席科学官。他在传染病领域带来了30多年的经验，最近于2020年至2023年担任索伦托医疗旗下Smartpharm Therapeutics的首席科学官。在那段时间里，他领导了开发针对新冠病毒的基因编码单克隆抗体的工作，这些抗体可以迅速适应新出现的令人担忧的变异。他还曾在索伦托医疗兼任抗病毒和溶瘤免疫疗法开发高级副总裁。在此之前，Allen博士于2018年至2020年在索伦托医疗担任溶瘤免疫疗法负责人，此前他曾在制药和生物技术行业担任多个高级科学职务，包括在SIGA科技和俄勒冈转化研究与发展研究所任职。Allen博士拥有哥伦比亚大学微生物学博士学位、乔治亚理工学院应用生物学硕士学位和罗德学院生物学学士学位。他在病毒学领域发表了大量文章，并在圣路易斯华盛顿大学和埃默里大学完成了病毒学博士后培训。
Robert Allen,has served as Chief Scientific Officer since April 2023. He has over 30 years of experience across the infectious disease space, most recently as the Chief Scientific Officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics, from 2020 to 2023. During that time, he led efforts to develop gene-encoded monoclonal antibodies for COVID-19 that could be quickly adapted to respond to emerging variants of concern. He also served concurrently as Senior Vice President, Antiviral and Oncolytic Immunotherapy Development, at Sorrento Therapeutics. Prior to this, Dr. Allen served as Head of Oncolytic Immunotherapy at Sorrento Therapeutics from 2018 to 2020, and he previously held multiple senior scientific roles across the pharmaceutical and biotechnology industries including at SIGA Technologies and the Oregon Translational Research and Development Institute. Dr. Allen holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College. He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University.- 罗伯特·艾伦，自2023年4月起担任首席科学官。他在传染病领域带来了30多年的经验，最近于2020年至2023年担任索伦托医疗旗下Smartpharm Therapeutics的首席科学官。在那段时间里，他领导了开发针对新冠病毒的基因编码单克隆抗体的工作，这些抗体可以迅速适应新出现的令人担忧的变异。他还曾在索伦托医疗兼任抗病毒和溶瘤免疫疗法开发高级副总裁。在此之前，Allen博士于2018年至2020年在索伦托医疗担任溶瘤免疫疗法负责人，此前他曾在制药和生物技术行业担任多个高级科学职务，包括在SIGA科技和俄勒冈转化研究与发展研究所任职。Allen博士拥有哥伦比亚大学微生物学博士学位、乔治亚理工学院应用生物学硕士学位和罗德学院生物学学士学位。他在病毒学领域发表了大量文章，并在圣路易斯华盛顿大学和埃默里大学完成了病毒学博士后培训。
- Robert Allen,has served as Chief Scientific Officer since April 2023. He has over 30 years of experience across the infectious disease space, most recently as the Chief Scientific Officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics, from 2020 to 2023. During that time, he led efforts to develop gene-encoded monoclonal antibodies for COVID-19 that could be quickly adapted to respond to emerging variants of concern. He also served concurrently as Senior Vice President, Antiviral and Oncolytic Immunotherapy Development, at Sorrento Therapeutics. Prior to this, Dr. Allen served as Head of Oncolytic Immunotherapy at Sorrento Therapeutics from 2018 to 2020, and he previously held multiple senior scientific roles across the pharmaceutical and biotechnology industries including at SIGA Technologies and the Oregon Translational Research and Development Institute. Dr. Allen holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College. He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University.
- Jill Andersen
Jill Andersen，自2021年11月起担任首席法务官和公司秘书。在加入Invivyd之前，Andersen女士于2020年6月至2021年10月担任Oyster Point Pharma，Inc.的总法律顾问、公司秘书和首席合规官。在加入Oyster Point之前，Andersen女士于2016年9月至2019年11月在新基医药公司担任副总裁兼法律、炎症和免疫学特许经营、美国市场准入和合同负责人，直到被百时美施贵宝公司收购，并于2019年11月至2020年5月担任法律副总裁。在加入Celgene之前，Andersen女士在诺华公司担任高级法律领导职务，包括2015年3月至2016年9月在诺华服务公司担任法律和知识产权全球资产副总裁兼总法律顾问，2014年2月至2015年3月在诺华消费者健康公司担任美国总法律顾问和合规官，以及2007年至2015年3月在诺华制药公司担任越来越多的职责。在加入制药行业之前，安德森女士曾于2003年至2007年担任新泽西州地区助理美国检察官。Andersen女士获得了波士顿学院的金融学士学位和维克森林大学法学院的法学博士学位。
Jill Andersen,has served as Chief Legal Officer and Corporate Secretary since November 2021. Prior to joining Invivyd, Ms. Andersen served as General Counsel, Corporate Secretary and Chief Compliance Officer of Oyster Point Pharma, Inc. from June 2020 to October 2021. Before joining Oyster Point, Ms. Andersen served as Vice President and Head of Legal, Inflammation & Immunology Franchise, U.S. Market Access and Contracts at Celgene Corporation from September 2016 to November 2019 until the acquisition by Bristol-Myers Squibb Company where she served as Vice President, Legal from November 2019 to May 2020. Prior to Celgene, Ms. Andersen held senior legal leadership roles within the Novartis companies, including Vice President and General Counsel, Legal & Intellectual Property Global Assets at Novartis Services, Inc. from March 2015 to September 2016, U.S. General Counsel and Compliance Officer at Novartis Consumer Health from February 2014 to March 2015, and roles of increasing responsibility at Novartis Pharmaceuticals Corporation from 2007 to March 2015. Before joining the pharmaceuticals industry, Ms. Andersen served as an Assistant United States Attorney for the District of New Jersey from 2003 to 2007. Ms. Andersen received a B.S. in Finance from Boston College and a J.D. from Wake Forest University School of Law.- Jill Andersen，自2021年11月起担任首席法务官和公司秘书。在加入Invivyd之前，Andersen女士于2020年6月至2021年10月担任Oyster Point Pharma，Inc.的总法律顾问、公司秘书和首席合规官。在加入Oyster Point之前，Andersen女士于2016年9月至2019年11月在新基医药公司担任副总裁兼法律、炎症和免疫学特许经营、美国市场准入和合同负责人，直到被百时美施贵宝公司收购，并于2019年11月至2020年5月担任法律副总裁。在加入Celgene之前，Andersen女士在诺华公司担任高级法律领导职务，包括2015年3月至2016年9月在诺华服务公司担任法律和知识产权全球资产副总裁兼总法律顾问，2014年2月至2015年3月在诺华消费者健康公司担任美国总法律顾问和合规官，以及2007年至2015年3月在诺华制药公司担任越来越多的职责。在加入制药行业之前，安德森女士曾于2003年至2007年担任新泽西州地区助理美国检察官。Andersen女士获得了波士顿学院的金融学士学位和维克森林大学法学院的法学博士学位。
- Jill Andersen,has served as Chief Legal Officer and Corporate Secretary since November 2021. Prior to joining Invivyd, Ms. Andersen served as General Counsel, Corporate Secretary and Chief Compliance Officer of Oyster Point Pharma, Inc. from June 2020 to October 2021. Before joining Oyster Point, Ms. Andersen served as Vice President and Head of Legal, Inflammation & Immunology Franchise, U.S. Market Access and Contracts at Celgene Corporation from September 2016 to November 2019 until the acquisition by Bristol-Myers Squibb Company where she served as Vice President, Legal from November 2019 to May 2020. Prior to Celgene, Ms. Andersen held senior legal leadership roles within the Novartis companies, including Vice President and General Counsel, Legal & Intellectual Property Global Assets at Novartis Services, Inc. from March 2015 to September 2016, U.S. General Counsel and Compliance Officer at Novartis Consumer Health from February 2014 to March 2015, and roles of increasing responsibility at Novartis Pharmaceuticals Corporation from 2007 to March 2015. Before joining the pharmaceuticals industry, Ms. Andersen served as an Assistant United States Attorney for the District of New Jersey from 2003 to 2007. Ms. Andersen received a B.S. in Finance from Boston College and a J.D. from Wake Forest University School of Law.
- Julie Green
Julie Green，自2024年1月起担任首席人力资源官，自2024年10月起担任传播主管。她于2022年1月加入Invivyd，在晋升为首席人力资源官之前曾担任人力资源高级副总裁。格林女士在人力资源事务方面拥有超过25年的经验。在加入Invivyd之前，Green女士于2018年至2022年担任Flexion Therapeutics的人力资源副总裁。从2012年到2018年，她创办并领导了自己的人力资源咨询公司，为各种组织提供战略建议和人力资源解决方案，专门从事生命科学领域。格林女士拥有巴布森学院的工商管理硕士学位和联合学院的心理学学士学位。
Julie Green,has served as Chief Human Resources Officer since January 2024, and as Head of Communications since October 2024. She joined Invivyd in January 2022 and served as Senior Vice President of Human Resources prior to her promotion to Chief Human Resources Officer. Ms. Green has more than 25 years of experience in human resources matters. Prior to joining Invivyd, Ms. Green was Vice President of Human Resources at Flexion Therapeutics from 2018 to 2022. From 2012 to 2018, she started and led her own human resources consulting firm offering strategic advice and human resources solutions to a variety of organizations, specializing in the life science space. Ms. Green holds an M.B.A. from Babson College and a B.S. in Psychology from Union College.- Julie Green，自2024年1月起担任首席人力资源官，自2024年10月起担任传播主管。她于2022年1月加入Invivyd，在晋升为首席人力资源官之前曾担任人力资源高级副总裁。格林女士在人力资源事务方面拥有超过25年的经验。在加入Invivyd之前，Green女士于2018年至2022年担任Flexion Therapeutics的人力资源副总裁。从2012年到2018年，她创办并领导了自己的人力资源咨询公司，为各种组织提供战略建议和人力资源解决方案，专门从事生命科学领域。格林女士拥有巴布森学院的工商管理硕士学位和联合学院的心理学学士学位。
- Julie Green,has served as Chief Human Resources Officer since January 2024, and as Head of Communications since October 2024. She joined Invivyd in January 2022 and served as Senior Vice President of Human Resources prior to her promotion to Chief Human Resources Officer. Ms. Green has more than 25 years of experience in human resources matters. Prior to joining Invivyd, Ms. Green was Vice President of Human Resources at Flexion Therapeutics from 2018 to 2022. From 2012 to 2018, she started and led her own human resources consulting firm offering strategic advice and human resources solutions to a variety of organizations, specializing in the life science space. Ms. Green holds an M.B.A. from Babson College and a B.S. in Psychology from Union College.
- Timothy Lee
Timothy Lee，自2024年6月起担任首席商务官。他带来了在生物技术和制药行业20多年的进步经验。在加入Invivyd之前，Lee先生于2020年2月至2024年6月在Amylyx Pharmaceuticals，Inc.担任销售、商业开发和全球商业培训负责人、副总裁。在此期间，他建立了发射能力和商业结构，导致Relyvrio为ALS患者成功商业发射。从2017年10月到2020年2月，Lee先生在Biohaven制药公司专注于罕见病组合和整体商业化战略。在其职业生涯的早期，Lee曾在亚力兄制药、诺华制药和辉瑞担任过越来越多的营销和销售职务。Lee先生拥有圣约瑟夫大学市场营销学士学位。
Timothy Lee,has served as Chief Commercial Officer since June 2024. He has more than 20 years of progressive experience in the biotechnology and pharmaceutical industries. Prior to joining Invivyd, Mr. Lee was Head, Vice President Sales, Commercial Development and Global Commercial Training at Amylyx Pharmaceuticals, Inc. from February 2020 to June 2024. During that time, he built launch capabilities and commercial structure that led to the successful commercial launch of Relyvrio for People Living with ALS. From October 2017 to February 2020, Mr. Lee focused on the rare disease portfolio and overall commercialization strategy at Biohaven Pharmaceuticals. Earlier in his career, Mr. Lee held roles of increasing responsibility in marketing and sales at Alexion Pharmaceuticals, Novartis Pharmaceuticals, and Pfizer. Mr. Lee holds a B.S. in Marketing from Saint Joseph's University.- Timothy Lee，自2024年6月起担任首席商务官。他带来了在生物技术和制药行业20多年的进步经验。在加入Invivyd之前，Lee先生于2020年2月至2024年6月在Amylyx Pharmaceuticals，Inc.担任销售、商业开发和全球商业培训负责人、副总裁。在此期间，他建立了发射能力和商业结构，导致Relyvrio为ALS患者成功商业发射。从2017年10月到2020年2月，Lee先生在Biohaven制药公司专注于罕见病组合和整体商业化战略。在其职业生涯的早期，Lee曾在亚力兄制药、诺华制药和辉瑞担任过越来越多的营销和销售职务。Lee先生拥有圣约瑟夫大学市场营销学士学位。
- Timothy Lee,has served as Chief Commercial Officer since June 2024. He has more than 20 years of progressive experience in the biotechnology and pharmaceutical industries. Prior to joining Invivyd, Mr. Lee was Head, Vice President Sales, Commercial Development and Global Commercial Training at Amylyx Pharmaceuticals, Inc. from February 2020 to June 2024. During that time, he built launch capabilities and commercial structure that led to the successful commercial launch of Relyvrio for People Living with ALS. From October 2017 to February 2020, Mr. Lee focused on the rare disease portfolio and overall commercialization strategy at Biohaven Pharmaceuticals. Earlier in his career, Mr. Lee held roles of increasing responsibility in marketing and sales at Alexion Pharmaceuticals, Novartis Pharmaceuticals, and Pfizer. Mr. Lee holds a B.S. in Marketing from Saint Joseph's University.